Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016, Article ID 6537248, 8 pages
http://dx.doi.org/10.1155/2016/6537248
Research Article

Serum HMGB1 Serves as a Novel Laboratory Indicator Reflecting Disease Activity and Treatment Response in Ankylosing Spondylitis Patients

1Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095th Jiefang Avenue, Wuhan, Hubei 430000, China
2Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China
3Department of Stomatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China

Received 28 April 2016; Accepted 10 July 2016

Academic Editor: Quanzhen Li

Copyright © 2016 Chenqiong Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Dakwar, J. Reddy, F. L. Vale, and J. S. Uribe, “A review of the pathogenesis of ankylosing spondylitis,” Neurosurgical Focus, vol. 24, no. 1, article E2, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. M. F. Shamji, M. Bafaquh, and E. Tsai, “The pathogenesis of ankylosing spondylitis,” Neurosurgical Focus, vol. 24, no. 1, article E3, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Ambarus, N. Yeremenko, P. P. Tak, and D. Baeten, “Pathogenesis of spondyloarthritis: autoimmune or autoinflammatory?” Current Opinion in Rheumatology, vol. 24, no. 4, pp. 351–358, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Dougados and D. Baeten, “Spondyloarthritis,” The Lancet, vol. 377, no. 9783, pp. 2127–2137, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. D. H. Quaden, L. M. De Winter, and V. Somers, “Detection of novel diagnostic antibodies in ankylosing spondylitis: an overview,” Autoimmunity Reviews, vol. 15, no. 8, pp. 820–832, 2016. View at Publisher · View at Google Scholar
  6. A. Cortes, J. Hadler, J. P. Pointon et al., “Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci,” Nature Genetics, vol. 45, no. 7, pp. 730–738, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. J. A. Smith, “Update on ankylosing spondylitis: current concepts in pathogenesis,” Current Allergy and Asthma Reports, vol. 15, no. 1, p. 489, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Sieper and D. Poddubnyy, “New evidence on the management of spondyloarthritis,” Nature Reviews Rheumatology, vol. 12, no. 5, pp. 282–295, 2016. View at Publisher · View at Google Scholar
  9. R. Pöllänen, T. Sillat, J. Pajarinen, J. Levón, E. Kaivosoja, and Y. T. Konttinen, “Microbial antigens mediate HLA-B27 diseases via TLRs,” Journal of Autoimmunity, vol. 32, no. 3-4, pp. 172–177, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Scaffidi, T. Misteli, and M. E. Bianchi, “Release of chromatin protein HMGB1 by necrotic cells triggers inflammation,” Nature, vol. 418, no. 6894, pp. 191–195, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. H. E. Harris, U. Andersson, and D. S. Pisetsky, “HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease,” Nature Reviews Rheumatology, vol. 8, no. 4, pp. 195–202, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. S. P. Jong, F. Gamboni-Robertson, Q. He et al., “High mobility group box 1 protein interacts with multiple Toll-like receptors,” American Journal of Physiology-Cell Physiology, vol. 290, no. 3, pp. C917–C924, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Yu, H. Wang, A. Ding et al., “HMGB1 signals through toll-like receptor (TLR) 4 and TLR2,” Shock, vol. 26, no. 2, pp. 174–179, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Yamaguchi, E. Sakai, H. Sakamoto et al., “Inhibitory effects of tert-butylhydroquinone on osteoclast differentiation via up-regulation of heme oxygenase-1 and down-regulation of HMGB1 release and NFATc1 expression,” Journal of Applied Toxicology, vol. 34, no. 1, pp. 49–56, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. J. P. Bidwell, J. Yang, and A. G. Robling, “Is HMGB1 an osteocyte alarmin?” Journal of Cellular Biochemistry, vol. 103, no. 6, pp. 1671–1680, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Oktayoglu, S. Em, M. Tahtasiz et al., “Elevated serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spondylitis and its association with disease activity and quality of life,” Rheumatology International, vol. 33, no. 5, pp. 1327–1331, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Chen, W. Sun, S.-X. Li et al., “Preliminary study of high mobility group box chromosomal protein 1(HMGB1) in ankylosing spondylitis patients,” Clinical and Experimental Rheumatology, vol. 33, no. 2, pp. 187–194, 2015. View at Google Scholar · View at Scopus
  18. S. van der Linden, H. A. Valkenburg, and A. Cats, “Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria,” Arthritis & Rheumatism, vol. 27, no. 4, pp. 361–368, 1984. View at Publisher · View at Google Scholar · View at Scopus
  19. J. M. Moll, “New criteria for the diagnosis of ankylosing spondylitis,” Scandinavian Journal of Rheumatology. Supplement, vol. 65, pp. 12–24, 1987. View at Google Scholar · View at Scopus
  20. K. L. Haywood, A. M. Garratt, and P. T. Dawes, “Patient-assessed health in ankylosing spondylitis: a structured review,” Rheumatology, vol. 44, no. 5, pp. 577–586, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Vastesaeger, B. V. Cruyssen, J. Mulero et al., “ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy,” Reumatologia Clinica, vol. 10, no. 4, pp. 204–209, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Calin, J.-P. Nakache, A. Gueguen, H. Zeidler, H. Mielants, and M. Dougados, “Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument?” Rheumatology, vol. 38, no. 9, pp. 878–882, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Danve and J. O'Dell, “The ongoing quest for biomarkers in Ankylosing Spondylitis,” International Journal of Rheumatic Diseases, vol. 18, no. 8, pp. 826–834, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. K. De Vlam, “Soluble and tissue biomarkers in ankylosing spondylitis,” Best Practice and Research: Clinical Rheumatology, vol. 24, no. 5, pp. 671–682, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Spoorenberg, D. van der Heijde, E. de Klerk et al., “Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis,” Journal of Rheumatology, vol. 26, no. 4, pp. 980–984, 1999. View at Google Scholar · View at Scopus
  26. J. Ruof and G. Stucki, “Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review,” The Journal of Rheumatology, vol. 26, no. 4, pp. 966–970, 1999. View at Google Scholar · View at Scopus
  27. M. Benhamou, L. Gossec, and M. Dougados, “Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs' treatment effect on C-reactive protein,” Rheumatology, vol. 49, no. 3, pp. 536–541, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Wang, O. Bloom, M. Zhang et al., “HMG-1 as a late mediator of endotoxin lethality in mice,” Science, vol. 285, no. 5425, pp. 248–251, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Abraham, J. Arcaroli, A. Carmody, H. Wang, and K. J. Tracey, “Cutting edge: HMG-1 as a mediator of acute lung inflammation,” The Journal of Immunology, vol. 165, no. 6, pp. 2950–2954, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Ruan, L. Wang, Y. Zhao et al., “Carbon monoxide potently prevents ischemia-induced high-mobility group box 1 translocation and release and protects against lethal renal ischemia-reperfusion injury,” Kidney International, vol. 86, no. 3, pp. 525–537, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. B. Krüger, S. Krick, N. Dhillon et al., “Donor toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 9, pp. 3390–3395, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. D. A. Abdulahad, J. Westra, J. Bijzet, P. C. Limburg, C. G. M. Kallenberg, and M. Bijl, “High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus,” Arthritis Research and Therapy, vol. 13, no. 3, article R71, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Ek, K. Popovic, H. E. Harris, C. S. Nauclér, and M. Wahren-Herlenius, “Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjögren's syndrome,” Arthritis and Rheumatism, vol. 54, no. 7, pp. 2289–2294, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Qin, Y. Chen, W. Wang et al., “HMGB1-LPS complex promotes transformation of osteoarthritis synovial fibroblasts to a rheumatoid arthritis synovial fibroblast-like phenotype,” Cell Death and Disease, vol. 5, no. 2, Article ID e1077, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Magna and D. S. Pisetsky, “The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases,” Molecular Medicine, vol. 20, no. 1, pp. 138–146, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. I.-H. Song, F. Heldmann, M. Rudwaleit et al., “Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial,” Arthritis & Rheumatism, vol. 62, no. 5, pp. 1290–1297, 2010. View at Publisher · View at Google Scholar · View at Scopus